Investors, Strategics & Innovators

Bio coming soon.

Scott will join his team of exclusive sponsors to host the Emerging Medtech Summit. Scott's mission at the meeting will be to connect the investors, innovators and strategics that are driving the future of medtech.

Scott is the President, CEO and Founder of Life Science Intelligence.  He has been in the medtech market intelligence business for over 20 years supporting venture funded startups, major strategics, and life science investors as they navigate the ever-changing medtech marketplace.  Prior to founding LSI, he held senior executive roles with renowned life science data providers including Medical Data International, Medtech Insight and Windhover Information.  He has held leadership roles as a strategic partner for Elsevier Business Intelligence, Health Research Intelligence, and Informa Business Intelligence.  Scott and his team at LSI have conducted numerous market research projects for top medical device manufacturers including Johnson & Johnson, Medtronic, Boston Scientific, Abbott, Becton Dickinson, Teleflex, Cardinal Health, GE Healthcare, and Stryker, among others. 

Bio coming soon.

Bio coming soon.

Bio comig soon.

Tyler J. Stowater is Partner and Vice President of Bluestem. He graduated from South Dakota State University with a BS Degree in Agriculture Economics (1984) and a MS Degree in Economics (1986). Tyler spent eleven years with the State of South Dakota's Bureau of Finance and Management. During his tenure, Tyler held the position of budget analyst, state economist, and deputy commissioner. In 1997, Tyler left the State to become an Assistant Vice President at Citibank South Dakota with business analysis responsibilities in the North American Cards Customer Service Unit. Tyler joined Bluestem in 2000 and is currently in charge of portfolio management with responsibilities including the evaluation of prospective companies, structuring, negotiating, and performing due diligence for various investments made by Bluestem. He monitors and provides assistance to existing portfolio companies and holds multiple Board of Director positions. In the spring of 2016, Tyler was given the Distinguished Alumnus award at the 62nd Annual Celebration of Excellence in Economics at South Dakota State University. Tyler is married to Joni (Klosterman) and they have two children, McKenzie (Otterberg) and McCord.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.

Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).

Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.

Sascha studied technology management in Munich, Singapore and Boston and  holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.

During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Dr. Marengère is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.

Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi Inc.; Acanthas Pharma; Occelaris Pharma; Ixchelsis; PRCL Pharma; Panthera Dental; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics as well as Rapid Micro Biosciences. Luc was on the Board of Colucid Pharma Inc. and Aurka Pharma which were recently sold to Eli Lilly for US $960M and US $575M respectively.

Dr. Marengère brings a significant track record to TVM given his long standing experience as  a Venture Capitalist. Very notable deals during Luc‘s previous tenure as Managing Partner at VG Partners include Cytochroma Inc. (sold to Opko for US$ 400M); VisualSonics (sold to Sonosite for US $75M) and CITA Neuropharma (sold to Vernalis Plc for US$ 85M). Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while at La Caisse De Depot‘s venture capital group SOFINOV as well as MDS Capital and MedTech Partners.

Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. Luc holds a Ph.D. from University of Toronto‘s department of Medical Biophysics and Molecular Genetics.

Mr. Sym-Smith is attending the Emerging Medtech Summit to identify new investment opportunities and scout the future of medtech.

David Sym-Smith, is a Partner at Mobility Ventures who is a 25 year mobile industry veteran with a solid record of building multi-million dollar operations from scratch along with profitable exits.  Most recently, David served as Interim CEO at IndoTraq, the developer the fastest and most precise wireless indoor 3-D tracking system.

David has served as senior executive of global corporations as well as at multiple startups. He has a proven record of success in launching new markets, turnarounds, starting new business groups, building sales channels, introducing new products and services, winning market share and exceeding revenue and sales goals. 

Prior to joining Mobility Ventures, David served as the Chief Strategy and Marketing Officer of Tele Atlas. David managed global marketing, strategic planning, and product development for this leading global provider of digital maps and location content. Company doubled in size and was sold to TomTom for over $3 Billion.  Previously David served as the SVP of Global Business Development and Marketing at InnoPath, where he managed global marketing, product development and business development for InnoPath the industry leader in over-the-air (OTA) software updates and mobile device management (MDM) solutions. He Increased market share to 70% and revenue by more than 100%. David also helped launch Command Audio Corporation as Senior Vice President of Global Sales and Marketing, successfully leading the company from beta to launch to spin-off,  growing the company from 20 to over 100 people with over $80M in funding from Tier 1 VC’s and strategic investors (partially acquired by iBiquity).

David was a member of the founding core management team of Aerial Communications, serving as Regional President; he helped grow the organization from a mobile telecom start-up from early pre-launch phase, to a large entity with a $1.1B market cap within one year and was sold thereafter for more than $3.0B to T-Mobile (VoiceStream). At Sprint Spectrum he led Marketing and Product Development in launching the first PCS network in the country and first GSM network in the Americas.  Helping build a startup into an 800-employee, $150M revenue business in only the second year of service, and exiting with Sprint PCS’s purchase of operating control

David has also held senior management positions at CellularOne, AT&T, GTE, Saint-Gobain (France) and The Hay Group. He holds an M.B.A. from Pennsylvania State University – Smeal College of Business.

Simon joined Sofinnova in 2021 after consulting for Corporates seeking to develop partnership with Digital Health companies. He worked closely with business development functions to identify, assess, and structure strategic investments. Prior to that, Simon was at Baxter International, where he was part of the External Innovation Department. At Baxter, Simon coordinated scouting activities and technical due diligence that assessed M&A opportunities.

He is a Board member at Gradientech AB, a privately held Swedish company developing ultra-rapid treatment decision tools for antibiotic susceptibility testing. He is also a Steering Committee member of the MedFIT conference, an international event that brings together key innovators in the MedTech, diagnostic and digital health sectors.

Simon enjoys constant exposure to novel technologies, curious and motivated people, and supporting the development of companies that are striving to improve medicine. He decided to join Sofinnova because of the strong team spirit and collective drive.

He has a B.Sc. in Biomedical Science from King’s College London and an M.Sc. in International Business from SKEMA Business School.

Mr. Mascarell will share the story of FineHeart at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities.

Arnaud started his career as a research engineer by Air Liquide in 1997. In 1998, he joined Medtronic where he had the opportunity to grow up in one of the world-class leading medtech. Senior executive with more than 17 years of experience managing sales, marketing, clinical, personal and merchandising at district and regional levels, Arnaud completed his academic training with a MBA from IAE Paris and a graduate from HEC Start Up. His taste for an entrepreneurial way let him co-found FineHeart in 2010.

Mr. Moran will attend the Emerging Medtech Summit to share the Motus GI story and discuss strategic partnering interests.  

Tim has served as Chief Executive Officer since October 1, 2018. Prior to joining us, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc (“Covidien”), an Irish headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.

Accomplished medical device executive renowned for strategic vision, leadership and global business acumen with a track record of success.

Dushyanth lead the Acute Care Franchise within Dr. Reddy’s innovation business for several years. His responsibilities included the commercialization strategy of acute care products, which was the company’s highest value portfolio. He has had a proven track record in product conceptualization, invention, development, and licensing of products and devices across a number of therapeutic areas. He was responsible for the entire US branded sales and marketing organization, while also managing the corporate development and M&A function. He also held senior leadership roles across portfolio optimization, alliance management, and strategic planning.

Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.

Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.

Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit serves as a board member at Navaux and an advisor to Fanisko, Triocula and UnityDx.

Successful Regenerative Medicine and MedTech entrepreneur. Currently Founder and CEO of Lumiheal Therapeutics.

Dr. Nadine Hachach-Haram is a surgeon, lecturer and clinical entrepreneur. She drew on her passion for innovation, education and global surgery to co-found Proximie, an augmented reality platform that allows doctors to virtually transport themselves into any operating room, anywhere in the world, to visually and practically interact in an operation from start to finish. From marking up a patient to providing real-time virtual presence in assisting and instructing on an operation, Proximie aims to provide safe, accessible and cost-effective surgery to every patient around the world. Dubbed the "future of surgery" by CNN, Proximie has gone from strength to strength and won multiple awards as well as being the main focus of the Foreign Press Association Science Story of the Year. It aims to revolutionize the delivery and education of healthcare by reducing the cost of that delivery while providing improved quality to the end patient, ensuring that every patient gets the best care, the first time, every time.

Dr. Mitchell will share the story of Novuson at the Emerging Medtech Summit and will discuss their financing objectives and strategic partnering plans.

Dr. Mitchell is a graduate of the University of Washington and he has been designing biomedical instrumentation and devices for approximately 20 years. Dr. Mitchell has extensive experience in biomechanics (soft tissue and orthopedic), tissue engineering, instrumentation, electronics, and mechanical design.

While at the university, Dr. Mitchell managed and conducted research in multimillion dollar DARPA projects where he developed relationships with medical industry leaders. He has conducted research in biomechanics, tissue engineering, acoustic hemostasis and high intensity focused ultrasound (HIFU) for tumor treatment. Dr. Mitchell has been involved in helping HIFU gain recognition in the clinical setting and has led research teams in conducting application studies.

Dr. Wood has 20+ years of experience championing innovative clinical solutions to the marketplace, from concept to revenue.

Dr. Wood most recently held the position of Executive Vice President of Marketing and Technology for Vital Images, an innovative advanced visualization software company. Prior to Vital Images, Dr. Wood served as VP of marketing at R2 Technology (now Hologic), where she championed the development, regulatory approval and commercial release of the first FDA approved (PMA) software product for the automatic detection of lung nodules in both diagnostic and screening chest CT examinations.

Dr. Wood received her Ph.D. from the Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.

Dr. Wood has been issued six patents in the field of computer-aided detection and quantitative imaging; authored numerous book chapters, peer-reviewed papers, abstracts, and served as a speaker at numerous conferences in the area of three-dimensional imaging of the thorax, quantitative imaging and computer-aided detection.

Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.

With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial. 

Mr. Borbath will share the story of Synergia Medical and the Emerging Medtech Summit and will discuss business, investment and partering updates.

Attila Borbath's M.Sc. in Business Administration and Engineering from the UCLouvain followed by the CEMS Master's in International Management naturally brought him to pave his professional way in a technological start-up in the finance sector for 10 years. 

In parallel, he obtained his Airline Transport Pilot License. He was then convinced by the idea of joining an innovative technology start-up where he had the role of VP Sales and Marketing. In 2013, he moved to Synergia Medical that he co-founded. Well-travelled, multilingual and energetic, Attila has developed remarkable management, entrepreneurial, marketing, and business development skills. 

Lloyd Diamond, a US citizen, is a seasoned medtech executive and CEO with 25 years of disruptive technology commercialization experience in the life science industry. He most recently served as the CEO of Precise Light Surgical, a commercially ready medical device company in Silicon Valley. Prior to that, he was the CEO of Bonesupport AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US which led to a successful IPO on the NASDAQ OMX in Stockholm. Lloyd has first-hand experience in the ophthalmology segment as he was responsible for managing Lumenis’ global surgical and vision franchises. He has commercialized many other disruptive technology platforms including at Kyphon and Laserscope. Lloyd received a dual degree in Biochemistry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at Arizona State University.

Mr. Preston will share the story of Centese and will discuss capital needs and strategic partnering interests.

Randy is Chief Business Officer of Centese Inc. He has over 15 years of experience in the medical device industry working with companies ranging from seed stage start-ups to Fortune 100. He has held key positions in business development, sales, marketing, and clinical research in both the US and EU. Randy holds a B.S. in Mechanical Engineering from California Polytechnic State University, San Luis Obispo.

Mr. Boaz Assaf will introduce Colospan's novel solution, the company's key achievements to date and will discuss investment and strategic partnering opportunities.

Boaz  is an entrepreneur with twenty years of experience in the medical device and high-tech industries. Boaz brings to Colospan a unique set of skills in sales, marketing, organizational, operational and strategic planning. Before founding Colospan, Boaz worked at Johnson & Johnson in Ethicon Endo Surgery Division and at Medport Ltd. 

Boaz holds a BA in Political Science and East Asia studies from Tel Aviv University and MBA from IDC Herzliya. 

Mr. Altman will share the story of CorInnova at the Emerging Medtech Summit and discuss oppportunities to invest in or partner with the company.

William provides executive management oversight drawing on 25 years' of experience building healthcare companies.  Mr. Altman is a former McKinsey & Co. consultant, and co-founded two firms that grew to over $50M revenues, including one healthcare services company that grew to 500 employees. He has served on the boards of five growth companies, including a 7,000 employee NASDAQ listed company which increased its market capitalization from $0.5 billion to $1.5 billion during his tenure, when it was successfully sold.  Previously, Mr. Altman served as President & CEO of Kardia Therapeutics, a regenerative medicine company engaged in developing adult cardiac stem cells for use in heart failure therapy.  A native of New Ulm, Texas (pop. 500), Mr. Altman earned a B.S. degree in Electrical Engineering from Texas A&M University, an M.A. in Politics and Economics from Oxford University as a Rhodes Scholar, and an M.B.A. from Harvard Business School.

Ben received a BS in Mechanical and Aerospace Engineering from the University of Virginia, where he focused on material science, biomedical engineering, and energy engineering. At the George Washington University, his work focused on new materials and 3-D printing for stem cell growth and orthopedic tissue repair. Dr. Holmes has been awarded several patents, published numerous journal articles, and contributed a chapter to the book Tissue and Organ Regeneration: Advances in Micro- and Nanotechnology (Pan Stanford Publishing, 2014). In addition to research, he has a strong record in entrepreneurship, having participated in the National Science Foundation’s I-Corps program on the local and national levels and VentrueWell’s ASPIRE program for medical device companies. Dr. Holmes has also demonstrated a strong early stage funding track record, bringing the company an National Science Foundation I-coprs grant, a Pediatric Orthopedic Society of North America research grant and most recently a Phase I SBIR award from the NSF. 

Mr. Colen will attend the Emerging Medtech Summit to share the Neovasc story and discuss strategic partnering objectives.

Fred Colen is a seasoned business executive with years of experience leading small, medium and large medical device businesses throughout the world. Fred has been a successful business innovator in commercialization of new medical technology products. He was President/CEO of BeneChill, a brain cooling company and President of the Boston Scientific Cardiac Rhythm Management Group. Furthermore he has served as Boston Scientifics’ Chief Technology Officer for eight years. Born and raised in the Netherlands, he obtained a Masters Degree in Electrical Engineering with specialization in BioMedical Technology from the RWTH Aachen, Germany. He has served on several Boards: Mölnlycke Healthcare, Middle Peak Medical and College of Science & Engineering at the University of Minnesota.

Mr. Klontz will share the story of New View Surgical at the Emerging Medtech Summit and discuss capital and partnering objectives for 2021.

Bryce is an accomplished global sales and marketing executive, having built and led commercial teams in the US, Europe and Asia. Most recently, Mr. Klontz was the Vice President of Commercial Strategy, Emerging Markets at Covidien, PLC where he led efforts to build commercial capabilities within the $1.5B+ Asia, Latin America, Emerging Europe, Middle East and Africa geographies. Mr. Klontz spent 14 years at Covidien in various leadership roles including Marketing Director in both the US and Europe, as well as 3 years as Vice President, Surgical Devices Business Unit, in Asia. Mr. Klontz also served as the global post-M&A integration lead for two of Covidien's most impactful acquisitions. Earlier in his career, Mr. Klontz played a pivotal role in the global launch of The CO2 Heart Laser System. Mr. Klontz received his MBA in marketing and finance from Carroll School of Management at Boston College and a Bachelor's degree from Northwestern University.

Mr. Atria will share the story of nView Medical at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities.

Cristian has consulted and worked for Fortune 100, start-up and private equity owned companies (GE Healthcare, Fiagon GmbH, HealthTronics, nView medical). With nView medical, Mr. Atria has successfully secured seed funding from private investors, successfully obtained Small Business Innovation Research grants (SBIRs) from the National Science Foundation (NSF) and built a superb team.  Prior to founding nView medical, Mr. Atria worked 13 years for GE Healthcare. His last role was General Manager with Global Profit & Loss responsibility where he ran an acquired start-up in the field of surgical navigation (VTI) and integrated it with GE OEC. Mr. Atria has developed and launched three major image guidance platforms and obtained five 510(k) clearances.  Mr. Atria holds two Masters of Science in Engineering from Supelec, Paris and Politecnico di Torino, Italy and an MBA from Boston University in Boston, Massachusetts.

Bryan will share the Pristine Surgical story at the Emerging Medtech Summit and discuss partnering and fundraising updates. 

Mr. Lord works with start-ups and investors to bring new med-tech, high-tech, clean-tech, and software products to the market and to help companies scale. He has experience as an executive, entrepreneur, advisor, deal facilitator, and investor. 

Mr. Biggins will represent Access Vascular at the Emerging Medtech Summit and will be available to discuss investment and strategic partnering objectives.

After shadowing physicians at a Boston Hospital and witnessing complications first-hand, James was compelled to design a better venous catheter. Before founding Access Vascular, James held product development, engineering, and clinical affairs roles at Ocular Therapeutix, Boston Scientific, and Medtronic, bringing over a dozen products from concept to commercialization.

Mr. Goel brings 15+ years of experience in medical device software/hardware design, specializing in the development of novel imaging, visualization, and analysis systems for vascular surgery. Working closely with surgeons, he developed a keen understanding of current clinical challenges and unmet needs, leading him to invent the IOPS™ technology.

Mr. Liu will share the Vena Vitals story at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities. 

Ray is an executive leader in healthcare technology, with expertise in building, launching, and running products and services for both startups and multinationals. Prior to Vena Vitals, he ran product and operations for Ediom, where he created hospital decision support tools that led to the company's acquisition by Vizient, Inc. Ray also led product for Socialwellth, where he directed the development and launch of a consumer health engagement platform that was rolled out to 15.2M users, leading to the company's acquisition by Cigna. 

At Siemens, Ray developed strategies, turnaround plans, and new market entries for the healthcare, energy, and industrial business units, and at GE Healthcare, he led the global launch of patient vital sign monitoring devices from China to the rest of the world. In addition to co-founding and running Vena Vitals, Ray also serves as an advisor to MDstewardship, a telemedicine company focused on antimicrobial stewardship. Ray holds an MBA from Harvard Business School, an MS from the University of California at Berkeley, and a BS from the University of Illinois at Urbana-Champaign. 

Mr. Shah will share the story of Nephrodite at Emerging Medtech Summit and will discuss partnering and investment opportunities.

Dr. Nikhil L. Shah currently serves as the System Chief for Minimally Invasive and Robotic Surgery at Piedmont Health Care based in Atlanta, Georgia. Dr. Shah has performed thousands of minimal access and robotic procedures with specific expertise in Genitourinary Oncology and urinary tract reconstruction. In addition, his interest and expertise in digital Surgery, intelligence, advanced-integrated imaging as well as automation as they apply to the patient-care continuum define his passion as a progressive Physician Leader.

Dr. Shah completed his undergraduate training at the University of Michigan and Medical School at the Kirksville College of Osteopathic Medicine. In medical school, Dr, Shah received a highly coveted research award funded in part by the National Institutes of Health. His training in General Surgery was at the Henry Ford Hospital in Detroit and followed with subspecialty training in Robotics, Laparoscopy and Urological Oncology at the Vattikuti Urology Institute at Henry Ford Health Systems in Detroit. During residency, Dr. Shah additionally completed a National Institutes of Health - National Institute of Diabetes and Kidney Urologist-Scientist Research Fellowship at the University of Michigan in Ann Arbor. Concurrently to his time in the laboratory, he completed a Master’s degree in Health Management & Policy at the University of Michigan’s School of Public Health and the Ross School of Business.

Dr. Shah is the recipient of numerous awards and has authored many peer-reviewed publications. He is acknowledged as an established leader in minimally invasive surgical applications. He holds an adjunct Associate Professorship at the Georgia Institute of Technology. Dr. Shah has made several appearances on CNN with Dr. Sanjay Gupta regarding Robotic Surgery and Men’s Health. In addition, Dr. Shah serves as an active advisor to the medical technology industry and the financial sector involved with innovative technology, medical devices, simulation and new surgical training applications.

Dr. Shah’s continues translational efforts by bridging the gap between health care issues, science and medicine. He speaks about the changes in health care from the perspective of a Physician Leader focusing on improving quality through metrics, analytics and outcomes analysis. Dr. Shah also continues to receive extramural funding in an effort to increase complimentary, preventive and advanced technology therapies to his patients.

Co-founder & CEO, Claude has more than twenty years of global experience in the Health Care industry in product & market development in pharmaceuticals & vaccines (Merck & Novartis). With extensive sales & marketing experience at the global and market level, including product launch, Claude led HPV vaccine blockbuster Gardasil regulatory, market development & commercial launch efforts. He also developed MenB vaccine, Bexsero, scientific platform, product profile & market development leading global marketing efforts through EMEA filing.

Bio coming soon.

Bruce Lichorowic is a highly accomplished entrepreneur and chief executive in the medical industries.

Former Positions of Note:

• President & CEO, Trak Surgical
• Managing Director, BlueFire Capital Partners
• President & CEO, Dynaptics Corporation

A 2013 graduate of MIT with a BS in Mechanical Engineering, Adam co-founded Vicarious Surgical in 2014 with Sammy Khalifa. Since 2010, he’s been an Emergency Medical Technician (EMT) on an ambulance in Cambridge serving the needs of the MIT community.

A global medical technology and health sciences executive, John Murphy has held leadership roles in large public companies, middle-market private equity businesses, and venture capital environments over the past 20 years. He holds graduate and undergraduate degrees in computer science and a MBA in international finance.

A serial entrepreneur and experienced leader at Fortune 500 companies and startups in the medical device, imaging, and capital equipment markets, Mr. Zemel has a long track record of raising capital and building high-performing teams to develop, launch and sell innovative new products.  Prior to founding Retia, Mr. Zemel had several leadership roles in engineering, marketing and sales at a capital equipment startup and Becton Dickinson. He also authored 23 approved or pending patents. Mr. Zemel received his MS in Mechanical Engineering from the Massachusetts Institute of Technology and his MBA from the Yale School of Management.

Bio coming soon.

Geert is a senior executive with more than 20 years of experience in strategy consulting, entrepreneurship and general management. He worked as a technology and strategy consultant for Accenture and The Boston Consulting Group. In 2013, he became entrepreneur and partner at life sciences compliance software company Polaris, building and managing the European and Asian businesses. He played a key role in the sale of the business to IQVIA in 2017, where he continued working in various roles, initially global commercial head for compliance solutions, owning global sales, marketing and customer success, and most recently General Manager for the Dutch IQVIA business. Geert holds a Master of Science degree in International Business Administration from the University of Maastricht, and an MBA degree from IESE in Barcelona. Geert has assumed his role as CEO with GATT Technologies effective March 2020.

Patrick is passionate about leading a team and organization dedicated to supporting healthcare professionals in the area of surgical oncology. Prior to Onkos Surgical, Patrick was Executive Vice President of PDI and President of PDI Healthcare where he was responsible for oversight of strategic initiatives as well as financial performance of the Healthcare Division.

Prior to joining PDI, Patrick developed a passion for the advancement of surgical oncology in multiple roles in R&D, Marketing and General Management with Howmedica (division of Pfizer) and Stryker. In his early days at Howmedica, Patrick was responsible for the development of and launch of the company’s first FDA cleared product offering in orthopedic oncology. Patrick also holds implant and instrument design patents in orthopedic surgery.

Daniel Hawkins is the founder and CEO of Avail Medsystems, a medical technology company creating a network where medical expertise sharing can occur between healthcare professionals and experts to and from the operating room anytime, anywhere.

Over the past 25 years in the medical technology field, Daniel’s mission has been to identify and close gaps that prevent patients from getting the best possible healthcare. He is an inventor on over 140 patents and applications, and has held roles in both large and emerging companies, including Advanced Cardiovascular Systems, Inc., Endologix, Restore Medical, EnteroMedics, and Intuitive Surgical. Daniel is a co-founder of Calibra Medical, acquired by Johnson & Johnson, and founder of Shockwave Medical, Inc. (NASDAQ: SWAV). 

Daniel has an MBA from Stanford University and a BS in Economics from The Wharton School of the University of Pennsylvania. In 2017, Daniel was honored by Goldman Sachs as one of its Top 100 Most Intriguing Entrepreneurs.

30+ years of healthcare executive leadership with accomplished track-record commercializing medical devices, drugs, and drug-device combinations

Progressive leadership at private, public, small start-up to multibillion-dollar organizations in the Medical Technology and Pharmaceutical industries

CEO of private and public companies with extensive board management and capital raising experience in the private and public markets

Minimally invasive general surgeon with more than 10 years of clinical experience. Medical inventor with multiple patents and clinical researcher with publications in international journals, especially in the field of post-operatory pain.

Len Pagliaro, PhD, has 21 years of experience with successful commercialization of biotechnology products, services, and licensing, following an academic career. He has managed R&D and business development teams, and brought product lines from concept through commercialization to acquisition. A small molecule oncology project he led was successfully partnered with TopoTarget, and is now in the clinic. Len managed the P&L for a business unit of Thermo Fisher Scientific selling tools for drug discovery before co-founding Siva. He is responsible for overall corporate strategy and financing.

Prior to joining IntraOp, Sanjay was the CFO at SoloPower. He previously was the Founding Senior Finance Executive at Signet Solar, a start-up funded with $70M of private equity and public funding from the German Government. Sanjay led Signet’s financing efforts while negotiating $100M in equipment contracts and $100M of customer contracts that helped ramp Company revenue to a $50M run rate in less than two years from inception. He has successfully raised capital from both private equity and government sources throughout his career. Sanjay has also worked as Director of Corporate Finance and Investor Relations at Intersil, where he was responsible for all financial planning of an $800 million business, including the management of the company’s annual strategic planning process. Over the course of his career, Sanjay has drafted corporate strategy, formulated and forecasted business outlook and has participated in over $1BN of M&A activity. He has extensive experience in managing investor relations, SEC reporting & compliance and financial due diligence. An operations oriented financial executive, Sanjay holds a BS in Electrical Engineering from the University of Pune, India, and an MBA in Finance from the Rochester Institute of Technology.

Thorsten Waloschek, MBA is an experienced executive from industry with a passion for bringing new and innovative products to market that have a positive impact on patients, their families and clinicians.

Timothy I. Still’s background includes over 30 years of experience in medical devices and diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. He has been directly responsible for building the commercial viability at many of his previous companies, five of which have been successfully acquired.

Timothy earned a B.S. degree in Biological Sciences from the University of California at Davis, and an MBA in Marketing and Entrepreneurship from the University of Southern California.

Bio coming soon.

Dr. Gura is a nephrologist with more than 50 years of clinical and research experience. He is a worldwide expert in dialysis technology and a clinical professor at UCLA's Geffen School of Medicine.

Physician passionate about impacting healthcare systems through innovation and cutting-edge technologies. Long-time health policy and patient advocate. Currently dedicated to turn artificial intelligence into actionable intelligence in surgical care at KelaHealth.

A practicing surgeon and surgical educator, Dr. Goel currently practices in the Vancouver, B.C. area and also serves on the University of British Columbia’s Faculty of Medicine in the Department of Orthopedic Surgery. He received his medical degree from the University of Manitoba, pursued his residency training in orthopedic surgery at the University of Calgary, and completed fellowship training in shoulder surgery at the University of Western Ontario and Harvard University. Goel has co-authored more than 30 publications, and is widely sought as a presenter on surgical techniques.

25 years of leadership & business development in medical device business management

I am a medical device executive with over twenty-five years of leadership experience spanning quality, engineering, and operations including product line, business integrations and new product launches, six-sigma implementations for both operations and business process, and US and global marketing in surgical and monitoring environments.

My marketing experiences span business development (target identification, business case development, diligence), product development (concept through commercialization), into tactical commercial execution bringing innovative solutions to new sites. Market segments span the "admit to discharge" care continuum including the highest acuity in the OR/ICU through terminal chronic care and home care environments.

My experiences are built upon a four years foundation of basic science research at a premier international research institution.

James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions. 

Ms. Holzberger is a 20 year seasoned leader in Enterprise Imaging and Radiology.  Prior to being appointed as the President and CEO in January 2022 she was the Senior Vice President and General Manager of Enterprise Imaging at Nuance Healthcare (soon to be acquired by Microsoft) leading go to market, product development and product strategy for the $190M Business Unit.  Key launches included AI workflow solutions for Radiologist documentation, communication and follow up solutions.  She holds an Engineering degree from Steven’s Institute of Technology and many business and leadership certificates from Harvard University’s Business School and the Stern School of Business.

Dr. John H. Wong is an associate professor in the Departments of Clinical Neurosciences and Radiology at the Cumming School of Medicine. He serves as Director of Cerebrovascular and Endovascular Neurosurgery and maintains a busy clinical practice almost exclusively dedicated to treating brain aneurysms and stroke. Dr. Wong received his medical education and neurosurgical training at the University of Alberta. After a one-year fellowship in neurovascular surgery at Yale University and further two-year specialization in interventional neuroradiology in New York City, he was recruited to Calgary in 2001. Since then, he has helped develop one of the most collaborative and productive neurovascular and stroke units in North America with colleagues in neurology, radiology, and neurosurgery.

Dr. Wong has co-authored numerous peer-reviewed manuscripts and has served on several grant review panels including for the Canadian Institute of Health Research and the National Institutes of Health in the U.S. He has held numerous local and national leadership roles including the provincial past president of the Alberta Neurosurgical Society for over a decade, previous Division Head of Neurosurgery at the University of Calgary, and is the current Vice President of the Canadian Neurosurgical Society. Dr. Wong received his MBA from The Wharton School of Business at the University of Pennsylvania where he earned a double major in Finance and Entrepreneurship & Innovation and was conferred the Dean’s Leadership Award.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Sandy joined Lumeda as Chief Executive Officer to lead the company in its product commercialization and growth phase.  A graduate of Harvard Business School (MBA), Mr. Zinke has over 20 years of global healthcare industry experience with innovative companies including Boston Scientific, Cynosure / Hologic and CDx Diagnostics.  Prior to joining Lumeda, he was Vice President of Marketing & Business Development with CDx Diagnostics, known for an advanced diagnostic platform used to preemptively detect cancer based on AI-enabled tissue analysis and 3D imaging.  Over the last 10 years he has led teams that have developed and commercialized more than a dozen products and programs. Sandy has a strong track record of success in building and leading cross-functional teams to drive global growth of healthcare companies with innovative medical device and diagnostics products. He brings to Lumeda significant domain expertise and a network of industry contacts to develop key relationships with medical thought leaders and commercial partners critical to accelerate the introduction of the company’s novel PDT technology to the clinic.

Mr. Vance was appointed President and CEO of Titan Medical in July 2022. Prior to being appointed, he served as an independent director for Titan Medical's Board of Directors and as the company's Human Resources/Compensation Committee Chair leading the company's compensation policies and philosophical direction.

Christopher is a West Point graduate with a master’s degree in Business Administration, as well as Healthcare Administration. He has over 20 years of medical device experience in both large strategic healthcare companies and successful startup companies.  Prior to his position as VP of Commercial Integration at Medtronic, he was CEO of Mazor Robotics, Inc. and Chief Commercial Officer of Mazor Robotics Ltd., companies that were acquired by Medtronic in December 2018.

Bio coming soon.

John has a strong track record as an executive in a range of Life Sciences and healthcare companies, covering both pre-revenue and commercial high growth companies. He has raised more than $130m of venture capital to date and taken two start-ups through to successful exit events, including the $330m acquisition of ApaTech Ltd by Baxter. John has gained strong operational experience across a range of business functions and organisations, including fulfilling combined CFO and COO roles for two private companies previously.

John holds a Bachelor’s degree in Organisational Psychology and is a member of the Chartered Institute of Management Accountants.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio comming soon.